---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-059564"
form_type: "8-K"
ticker: "CC"
cik: "0001627223"
company_name: "Chemours Co"
filed_at: "2026-02-19T23:59:59+00:00"
generated_at: "2026-05-16T01:45:08.701978+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Chemours Q4 net loss widens to $47M; full year 2026 outlook: Adj. EBITDA $800M-$900M

## Summary
- Q4 net loss $47M (-$0.31/diluted) vs loss $11M (-$0.08) YoY; adjusted net income $7M ($0.05) vs $14M ($0.09).
- Q4 adjusted EBITDA $128M vs $168M YoY; net sales $1.3B slightly down; TSS segment record Q4 with 37% Opteon revenue growth.
- Full year 2025 net loss $386M (-$2.57/diluted) vs net income $69M ($0.46) prior year; adjusted net income $143M ($0.95) vs $179M ($1.19).
- Full year 2026 outlook: net sales growth 3-5%, adjusted EBITDA $800-$900M, free cash flow conversion above 25%.
- Announced sale of former Kuan Yin TiO2 site for ~$300M net proceeds on Jan 15, 2026.

## SEC filing metadata
- accession: 0001193125-26-059564
- form_type: 8-K
- ticker: CC
- cik: 0001627223
- company_name: Chemours Co
- filed_at: 2026-02-19T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1627223/000119312526059564/0001193125-26-059564-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1627223/000119312526059564/cc-20260219.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-059564
- JSON: https://secwatch.observer/filing/0001193125-26-059564.json
- Plain text: https://secwatch.observer/filing/0001193125-26-059564.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.